P525: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ENTOSPLETINIB ADDED TO INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN NEWLY DIAGNOSED NPM1-MUTATED AML

• J. C. Byrd,
• J. E. Cortes,
• M. D. Minden,
• T. Oellerich,
• E. M. Stein,
• J. Elder,
• P. Kumar,
• G. Bray,
• J. DiMartino,
• W. Stock

Affiliations

J. C. Byrd

1 University of Cincinnati, Cincinnati

J. E. Cortes

2 Georgia Cancer Center at Augusta University, Augusta, United States of America

M. D. Minden

3 Princess Margaret Cancer Centre, Toronto, Canada

T. Oellerich

4 Frankfurt Cancer Institute, Frankfurt am Main, Germany

E. M. Stein

5 Memorial Sloan Kettering Cancer Center, New York

J. Elder

6 PharPoint Research, Inc., Durham

P. Kumar

7 Kronos Bio, Inc., San Mateo

G. Bray

7 Kronos Bio, Inc., San Mateo

J. DiMartino

7 Kronos Bio, Inc., San Mateo

W. Stock

8 University of Chicago Medicine, Chicago, United States of America